FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075808045> ?p ?o ?g. }

• W2075808045 endingPage "1118" @default.
• W2075808045 startingPage "1111" @default.
• W2075808045 abstract "In the pathogenesis of neuropathic pain, the conversion of astrocytes in the reactive state and the ras-dependent Erk-mediated pathway play an important role. Zoledronic acid (ZOL) is a potent inhibitor of the latter pathway, but its activity in neurological diseases is hampered by its biodistribution that is almost exclusively limited to the bone. We have developed nanotechnological devices able to increase the accumulation of ZOL in extra bone sites. In this work, we have evaluated the effects of ZOL-encapsulating PEGylated liposomes (LipoZOL) on an animal model of neuropathic pain. We have found that 2 iv administrations (10 μg of ZOL, either as free or encapsulated into liposomes) at days 2 and 4 after the injury markedly reduced mechanical hypersensitivity at 3 and 7 days after nerve injury. On the other hand, free ZOL did not exert any significant alteration of the mechanical threshold. Immunohistochemical analysis of spinal cord revealed that GFAP-labeled astrocytes appeared hypertrophic activated cells in the ispilateral dorsal horn of spinal cord 7 days after SNI. LipoZOL significantly changed astrocyte morphology, by inducing a protective phenotype, without changing the total cell number. Moreover, the astrocytes of the spinal cord of LipoZOL-treated mice were positive for interleukin-10. Delivery of ZOL into the CNS was confirmed by biodistribution of fluorescently labeled liposomes. In particular, liposomes accumulated in the liver and kidney in both groups of normal and neuropathic animals; on the other hand, only in the case of neuropathic animals, a fluorescence increase in the brain and spinal cord occurred only in neuropathic animals at 30 min and 1 h. These data demonstrate that ZOL, only by using a delivery system able to cross the altered BBB, could be a new opportunity to treat neuropathic pain." @default.
• W2075808045 created "2016-06-24" @default.
• W2075808045 creator A5002742138 @default.
• W2075808045 creator A5007203413 @default.
• W2075808045 creator A5035904217 @default.
• W2075808045 creator A5037894517 @default.
• W2075808045 creator A5041819596 @default.
• W2075808045 creator A5044807555 @default.
• W2075808045 creator A5047470778 @default.
• W2075808045 creator A5050677254 @default.
• W2075808045 creator A5052789598 @default.
• W2075808045 creator A5061433350 @default.
• W2075808045 creator A5071201867 @default.
• W2075808045 creator A5073891277 @default.
• W2075808045 creator A5085015375 @default.
• W2075808045 date "2013-02-14" @default.
• W2075808045 modified "2023-09-23" @default.
• W2075808045 title "Stealth Liposomes Encapsulating Zoledronic Acid: A New Opportunity To Treat Neuropathic Pain" @default.
• W2075808045 cites W1841237986 @default.
• W2075808045 cites W1966305311 @default.
• W2075808045 cites W1972659294 @default.
• W2075808045 cites W1978029175 @default.
• W2075808045 cites W1979859079 @default.
• W2075808045 cites W1982855449 @default.
• W2075808045 cites W1986129921 @default.
• W2075808045 cites W1990216374 @default.
• W2075808045 cites W1996523699 @default.
• W2075808045 cites W2003674452 @default.
• W2075808045 cites W2006161356 @default.
• W2075808045 cites W2009058800 @default.
• W2075808045 cites W2023952534 @default.
• W2075808045 cites W2031855873 @default.
• W2075808045 cites W2046335075 @default.
• W2075808045 cites W2047010161 @default.
• W2075808045 cites W2048954391 @default.
• W2075808045 cites W2056688527 @default.
• W2075808045 cites W2059646315 @default.
• W2075808045 cites W2068128655 @default.
• W2075808045 cites W2073842317 @default.
• W2075808045 cites W2075715972 @default.
• W2075808045 cites W2075944492 @default.
• W2075808045 cites W2076769374 @default.
• W2075808045 cites W2077358692 @default.
• W2075808045 cites W2077885131 @default.
• W2075808045 cites W2078800769 @default.
• W2075808045 cites W2084605244 @default.
• W2075808045 cites W2089079020 @default.
• W2075808045 cites W2094660330 @default.
• W2075808045 cites W2106360230 @default.
• W2075808045 cites W2106712353 @default.
• W2075808045 cites W2117634037 @default.
• W2075808045 cites W2122778405 @default.
• W2075808045 cites W2126005618 @default.
• W2075808045 cites W2128677683 @default.
• W2075808045 cites W2133362776 @default.
• W2075808045 cites W2139743596 @default.
• W2075808045 cites W2146990673 @default.
• W2075808045 cites W2149599746 @default.
• W2075808045 cites W2151561513 @default.
• W2075808045 cites W2164465986 @default.
• W2075808045 cites W2168604626 @default.
• W2075808045 doi "https://doi.org/10.1021/mp3006215" @default.
• W2075808045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23327778" @default.
• W2075808045 hasPublicationYear "2013" @default.
• W2075808045 type Work @default.
• W2075808045 sameAs 2075808045 @default.
• W2075808045 citedByCount "22" @default.
• W2075808045 countsByYear W20758080452013 @default.
• W2075808045 countsByYear W20758080452014 @default.
• W2075808045 countsByYear W20758080452016 @default.
• W2075808045 countsByYear W20758080452017 @default.
• W2075808045 countsByYear W20758080452019 @default.
• W2075808045 countsByYear W20758080452020 @default.
• W2075808045 countsByYear W20758080452022 @default.
• W2075808045 crossrefType "journal-article" @default.
• W2075808045 hasAuthorship W2075808045A5002742138 @default.
• W2075808045 hasAuthorship W2075808045A5007203413 @default.
• W2075808045 hasAuthorship W2075808045A5035904217 @default.
• W2075808045 hasAuthorship W2075808045A5037894517 @default.
• W2075808045 hasAuthorship W2075808045A5041819596 @default.
• W2075808045 hasAuthorship W2075808045A5044807555 @default.
• W2075808045 hasAuthorship W2075808045A5047470778 @default.
• W2075808045 hasAuthorship W2075808045A5050677254 @default.
• W2075808045 hasAuthorship W2075808045A5052789598 @default.
• W2075808045 hasAuthorship W2075808045A5061433350 @default.
• W2075808045 hasAuthorship W2075808045A5071201867 @default.
• W2075808045 hasAuthorship W2075808045A5073891277 @default.
• W2075808045 hasAuthorship W2075808045A5085015375 @default.
• W2075808045 hasConcept C118552586 @default.
• W2075808045 hasConcept C126322002 @default.
• W2075808045 hasConcept C16993767 @default.
• W2075808045 hasConcept C185154212 @default.
• W2075808045 hasConcept C185592680 @default.
• W2075808045 hasConcept C202751555 @default.
• W2075808045 hasConcept C2775991916 @default.
• W2075808045 hasConcept C2776326535 @default.
• W2075808045 hasConcept C2777107010 @default.
• W2075808045 hasConcept C2777542381 @default.

• next